Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CG Oncology, Inc. (CGON : NSDQ)

• Company Description    CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif. Number of Employees: 113

• Price / Volume Information    Yesterday's Closing Price: $57.76 Daily Weekly Monthly 20 Day Moving Average: 778,357 shares Shares Outstanding: 84.43 (millions) Market Capitalization: $4,876.98 (millions) Beta: 1.18 52 Week High: $60.00 52 Week Low: $14.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.29% 7.76% 12 Week 34.95% 34.26% Year To Date 39.11% 38.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 SPECTRUM CENTER DRIVE SUITE 2040 - IRVINE,CA 92618 USA ph: 949-409-3700 fax: - ir@cgoncology.com https://cgoncology.com

• General Corporate Information    Officers Arthur Kuan - Chief Executive Officer and Chairman Jim DeTore - Interim Principal Financial and Accounting Officer Susan Graf - Director Brian Liu - Director James J. Mule - Director Peer Information CG Oncology, Inc. (CORR.) CG Oncology, Inc. (RSPI) CG Oncology, Inc. (CGXP) CG Oncology, Inc. (BGEN) CG Oncology, Inc. (GTBP) CG Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 156944100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/12/26 Share - Related Items Shares Outstanding: 84.43 Most Recent Split Date: (:1) Beta: 1.18 Market Capitalization: $4,876.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 50.28% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.40 Price/Cash Flow: - Price / Sales: 7,367.02 EPS Growth vs. Year Ago Period: -6.25% vs. Previous Quarter: 10.53% Sales Growth vs. Year Ago Period: 409.21% vs. Previous Quarter: 39.38% ROE 12/31/25 - -23.42 09/30/25 - -21.67 06/30/25 - -19.37 ROA 12/31/25 - -22.36 09/30/25 - -20.79 06/30/25 - -18.72 Current Ratio 12/31/25 - - 09/30/25 - 22.79 06/30/25 - 22.15 Quick Ratio 12/31/25 - - 09/30/25 - 22.74 06/30/25 - 22.15 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -6,967.98 06/30/25 - -23,245.19 Book Value 12/31/25 - - 09/30/25 - 9.02 06/30/25 - 8.79 Inventory Turnover 12/31/25 - - 09/30/25 - 4.20 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.43 06/30/25 - 0.00

Powered by Zacks Investment Research ©